• News & Media
  • Contact
  • Home
  • About Us
    • Our Commitment
    • The Story Behind Our Name
    • Leadership
    • Board of Directors
  • Our Approach
    • Precision Medicines
    • Overcoming Resistance
    • Novel Biomarkers
  • Pipeline
    • Ziftomenib
    • Tipifarnib
    • KO-2806
    • Posters and Presentations
    • Scientific Manuscripts
    • Access To Investigational Drugs Outside a Clinical Study
  • Clinical Trials
    • Overview of Clinical Trials
    • Ziftomenib Clinical Trials
    • KOMET-001 – AML
    • KOMET-007 – AML
    • KOMET-008 – AML
    • Tipifarnib Clinical Trials
    • KURRENT-HN – HNSCC
    • KO-2806 Clinical Trials
    • FIT-001 – Solid Tumors
  • Patients & Caregivers
    • Acute Leukemias
    • Head & Neck Cancer
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financial Information
    • Analyst Coverage
    • FAQs
    • Contact
  • Careers
    • Values
    • Life At Kura
    • Benefits
    • Open Positions
  • News & Media
  • Contact
  • Menu Menu

Media Coverage

Moving Forward, Giving Back: The ROI of Social Impact

The Life Science Cares Podcast

Kura Oncology’s President & CEO, Troy Wilson, joined Life Science Cares on their Moving Forward, Giving Back podcast to speak to the importance of social impact and philanthropic work and the return on investment (ROI) in a corporate setting.

Kura’s efforts, in tandem with Life Science Cares, support the potential for near-term local impact and long-term systemic impact in the local communities of San Diego and Boston, and help to create a true culture of care across the team.

Troy and the Kura team see social impact as a key measure of success. In fact, since Kura amped up its social impact efforts, the company has seen lower employee turnover rates compared to the industry average. Through pulse surveys, they can in part attribute this to the space Kura leadership provides for employees to give back within work hours, and to causes and organizations aligned with their values and located in their own communities.

Listen to the full podcast episode to hear perspectives from Troy along with host Morgan Berman, Executive Director of Life Science Cares Philadelphia, and guests Kate Wilson, President of the Gilead Sciences Foundation, Matthew Gline, CEO of Roivant Sciences, and Tom Croce, Vice President of Global Patient Advocacy at Jazz Pharmaceuticals.

Want to learn more about Kura’s values and culture of care? Visit our careers page!

Listen to Moving Forward, Giving Back: The ROI of Social Impact Listen to all episodes of Moving Forward, Giving Back Back to News & Media
  • About Us
  • Our Commitment
  • The Story Behind Our Name
  • Leadership
  • Board of Directors
  • Our Approach
  • Precision Medicines
  • Overcoming Resistance
  • Novel Biomarkers
  • Pipeline
  • Ziftomenib
  • Tipifarnib
  • KO-2806
  • Posters and Presentations
  • Scientific Manuscripts
  • Access to Investigational Drugs Outside a Clinical Study
  • Clinical Trials
  • Overview of Clinical Trials
  • Ziftomenib Clinical Trials
  • KOMET-001 – AML
  • KOMET-007 – AML
  • KOMET-008 – AML
  • Tipifarnib Clinical Trials
  • KURRENT-HN – HNSCC
  • KO-2806 Clinical Trials
  • FIT-001 – Solid Tumors
  • Patients & Caregivers
  • Acute Leukemias
  • Head & Neck Cancer
  • Investors
  • Overview
  • Press Releases
  • Events & Presentations
  • Corporate Governance
  • Financial Information
  • Analyst Coverage
  • FAQs
  • Contact
  • Careers
  • Values
  • Life at Kura
  • Benefits
  • Open Positions
  • News & Media
  • Press Releases
  • News & Perspectives
  • Expert Perspectives
  • Media Resources
  • Contact

Kura Oncology, Inc.
12730 High Bluff Drive, Suite 400
San Diego, CA 92130
(858) 500-8800

Kura Oncology, Inc.
2 Seaport Lane, Suite 8A
Boston, MA 02210
(617) 588-3755

Kura Oncology, Inc.
5510 Morehouse Drive, Suite 110
San Diego, California 92121

© 2025 Kura Oncology, Inc. All Rights Reserved | Terms of Use | Privacy Policy

Scroll to top Scroll to top Scroll to top